business strategy

News

AstraZeneca sets lofty target of $80bn in revenues by 2030

AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by

News

Internal budgets ‘holding back pharma’s digital evolution’

Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.

News

Novavax investor withdraws proxy fight after Sanofi deal

Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi.

News

Novavax's chief executive John Jacobs (l) and Shah Capital's founder Himanshu Shah (r)

Activist investor urges changes to Novavax board

Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter

News

Activist hedge fund seeks big shake-up at Novavax

Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

AstraZeneca sets lofty target of $80bn in revenues by 2030

Internal budgets ‘holding back pharma’s digital evolution’

Novavax investor withdraws proxy fight after Sanofi deal

Activist investor urges changes to Novavax board

Activist hedge fund seeks big shake-up at Novavax

Exscientia trims pipeline to focus on top cancer prospects

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

business strategy

Editor's Picks